Innate Pharma : TELLOMAK on hold
>TELLOMAK trial placed on clinical hold - This morning, Innate announced it would no longer treat new patients with its IPH4102 compound (lacutamab) in the TELLOMAK trial (cutaneous T-cell lymphoma). This decision follows a quality issue in the drug’s pharmaceutical development process. The subcontractor involved in manufacturing the product, Rentschler Fill Solutions GmbH or RFS, had apparently withdrawn the compliance certificate from batches produced, including the...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.